Faruqi & Faruqi, LLP, a prominent national securities law firm, is investigating potential claims on behalf of investors who suffered losses related to Jasper Therapeutics, Inc. (NASDAQ: JSPR). The firm has set a deadline of November 18, 2025, for investors wishing to seek the role of lead plaintiff in a federal securities class action against the company.
Investors who purchased or acquired securities in Jasper between November 30, 2023, and July 3, 2025, are encouraged to contact James (Josh) Wilson, a partner at Faruqi & Faruqi, for a discussion on their legal options. Wilson can be reached directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
The investigation stems from allegations that Jasper and its executives violated federal securities laws. The complaint claims that the company made false and misleading statements, failing to disclose critical information regarding its manufacturing processes and the viability of its product, briquilimab. Specifically, it is alleged that:
1. Jasper lacked adequate controls to ensure that third-party manufacturers complied with current Good Manufacturing Practices (cGMP).
2. This failure increased the risk of flawed study results, adversely affecting the regulatory and commercial prospects of the company’s products.
3. The situation led to potential cost-reduction measures that could disrupt business operations.
4. Consequently, the company’s financial outlook and the prospects for briquilimab were overstated.
The situation intensified following a press release from Jasper on July 7, 2025, which reported complications arising from the BEACON Study. The release indicated that results from specific dosage cohorts were confounded due to issues with a drug product lot, affecting 10 out of 13 patients treated with that lot. Jasper announced that it was investigating the issue and would halt studies related to asthma while focusing on advancing briquilimab for chronic spontaneous urticaria (CSU).
In light of this news, Jasper’s stock price plummeted by $3.73 per share, a decrease of 55.1%, closing at $3.04 on the same day. Investors are reminded that the lead plaintiff in a class action is typically the one with the largest financial interest in the case, who can adequately represent the interests of all affected investors.
Members of the putative class may choose to file a motion to serve as lead plaintiff through their selected counsel or may opt to remain absent from the proceedings. Importantly, participation in the class action will not impact an individual’s ability to share in any potential recovery.
Faruqi & Faruqi also invites anyone with information regarding Jasper’s operations, including whistleblowers and former employees, to reach out to the firm. Interested parties can find more details about the class action on the firm’s website or by contacting Josh Wilson directly.
For continuous updates, individuals can follow Faruqi & Faruqi on LinkedIn, X, or Facebook. As a reminder, this communication is considered attorney advertising, and prior results do not guarantee similar outcomes in future matters.
